Sareum Hldgs Plc (SAR) - Total Liabilities

Latest as of June 2025: £1.95 Million GBP ≈ $2.62 Million USD

Based on the latest financial reports, Sareum Hldgs Plc (SAR) has total liabilities worth £1.95 Million GBP (≈ $2.62 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SAR year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Sareum Hldgs Plc - Total Liabilities Trend (2004–2025)

This chart illustrates how Sareum Hldgs Plc's total liabilities have evolved over time, based on quarterly financial data. See Sareum Hldgs Plc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Sareum Hldgs Plc Competitors by Total Liabilities

The table below lists competitors of Sareum Hldgs Plc ranked by their total liabilities.

Company Country Total Liabilities
Cubic Digital Technology Co Ltd
SHE:300344
China CN¥144.52 Million
KD Chem Co. Ltd
KQ:221980
Korea ₩36.08 Billion
Crest Builder Holdings Bhd
KLSE:8591
Malaysia RM1.04 Billion
Kronologi Asia Bhd
KLSE:0176
Malaysia RM111.87 Million
NexgenRX Inc.
V:NXG
Canada CA$30.91 Million
Lyka Labs Limited
NSE:LYKALABS
India Rs664.32 Million
Hansung Ent
KO:003680
Korea ₩176.32 Billion
Rossell India Limited
NSE:ROSSELLIND
India Rs1.12 Billion

Liability Composition Analysis (2004–2025)

This chart breaks down Sareum Hldgs Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sareum Hldgs Plc stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.17 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.86 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sareum Hldgs Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sareum Hldgs Plc (2004–2025)

The table below shows the annual total liabilities of Sareum Hldgs Plc from 2004 to 2025.

Year Total Liabilities Change
2025-06-30 £1.95 Million
≈ $2.62 Million
+199.08%
2024-06-30 £653.00K
≈ $876.92K
-24.68%
2023-06-30 £867.00K
≈ $1.16 Million
+90.55%
2022-06-30 £455.00K
≈ $611.02K
+60.12%
2021-06-30 £284.15K
≈ $381.59K
+43.12%
2020-06-30 £198.54K
≈ $266.62K
+35.13%
2019-06-30 £146.93K
≈ $197.31K
-19.91%
2018-06-30 £183.46K
≈ $246.36K
+17.95%
2017-06-30 £155.53K
≈ $208.87K
+56.24%
2016-06-30 £99.55K
≈ $133.69K
+47.61%
2015-06-30 £67.44K
≈ $90.57K
+2.48%
2014-06-30 £65.81K
≈ $88.38K
-17.66%
2013-06-30 £79.92K
≈ $107.33K
-34.96%
2012-06-30 £122.87K
≈ $165.01K
+26.67%
2011-06-30 £97.00K
≈ $130.26K
0.00%
2010-06-30 £97.00K
≈ $130.26K
+86.54%
2009-06-30 £52.00K
≈ $69.83K
-88.15%
2008-06-30 £439.00K
≈ $589.54K
-62.70%
2007-06-30 £1.18 Million
≈ $1.58 Million
+102.93%
2006-06-30 £580.00K
≈ $778.89K
+22.88%
2005-06-30 £472.00K
≈ $633.85K
-41.73%
2004-06-30 £810.00K
≈ $1.09 Million
--

About Sareum Hldgs Plc

LSE:SAR UK Biotechnology
Market Cap
$4.26 Billion
£3.18 Billion GBP
Market Cap Rank
#24523 Global
#234 in UK
Share Price
£23.00
Change (1 day)
+9.52%
52-Week Range
£12.00 - £27.50
All Time High
£457.50
About

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more